Emodin Inhibits Vascular Endothelial Growth Factor-A-induced Angiogenesis by Blocking Receptor-2 (KDR/Flk-1) Phosphorylation
Overview
Authors
Affiliations
Emodin (1,3,8-trihydroxy-6-methylanthraquinone), an active component in the root and rhizome of Rheum palmatum, is a tyrosine kinase inhibitor with a number of biological activities, including antitumor effects. Here, we examine the effects of emodin on vascular endothelial growth factor (VEGF)-A-induced angiogenesis, both in vitro and in vivo. In vitro, emodin dose-dependently inhibits proliferation, migration into the denuded area, invasion through a layer of Matrigel and tube formation of human umbilical vein endothelial cells (HUVECs) stimulated with VEGF-A. Emodin also inhibits basic fibroblast growth factor-induced proliferation and migration of HUVECs and VEGF-A-induced tube formation of human dermal microvascular endothelial cells. Specifically, emodin induces the cell cycle arrest of HUVECs in the G0/G1 phase by suppressing cyclin D1 and E expression and retinoblastoma protein phosphorylation, and suppresses Matrigel invasion by inhibiting the basal secretion of matrix metalloproteinase-2 and VEGF-A-stimulated urokinase plasminogen activator receptor expression. Additionally, emodin effectively inhibits phosphorylation of VEGF-A receptor-2 (KDR/Flk-1) and downstream effector molecules, including focal adhesion kinase, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, Akt and endothelial nitric oxide synthase. In vivo, emodin strongly suppresses neovessel formation in the chorioallantoic membrane of chick and VEGF-A-induced angiogenesis of the Matrigel plug in mice. Our data collectively demonstrate that emodin effectively inhibits VEGF-A-induced angiogenesis in vitro and in vivo. Moreover, inhibition of phosphorylation of KDR/Flk-1 and downstream effector molecules is a possible underlying mechanism of the anti-angiogenic activity of emodin. Based on these data, we propose that an interaction of emodin with KDR/Flk-1 may be involved in the inhibitory function of emodin toward VEGF-A-induced angiogenesis in vitro and responsible for its potent anti-angiogenic in vivo.
Sun D, Wu L, Lan S, Chi X, Wu Z PeerJ. 2024; 12:e17534.
PMID: 38948219 PMC: 11214739. DOI: 10.7717/peerj.17534.
Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.
Kumari R, Syeda S, Shrivastava A Curr Med Chem. 2024; 31(32):5281-5304.
PMID: 38425113 DOI: 10.2174/0109298673282525240222050051.
Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer.
Okon E, Gawel-Beben K, Jarzab A, Koch W, Kukula-Koch W, Wawruszak A Int J Mol Sci. 2023; 24(21).
PMID: 37958772 PMC: 10648492. DOI: 10.3390/ijms242115789.
Emodin coupled with high LET neutron beam-a novel approach to treat on glioblastoma.
Kim J, Jung C, Lee W, Jeong H, Park M, Jang W J Radiat Res. 2022; 63(6):817-827.
PMID: 36253116 PMC: 9726713. DOI: 10.1093/jrr/rrac061.
Petrova K, Backorova M, Demcisakova Z, Petrovova E, Goga M, Vilkova M Life (Basel). 2022; 12(9).
PMID: 36143480 PMC: 9503005. DOI: 10.3390/life12091444.